Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Non-Current Assets (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Non-Current Assets for 6 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 40.93% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.5 million, a 41.92% decrease, with the full-year FY2024 number at $1.6 million, down 40.6% from a year prior.
  • Non-Current Assets was $1.2 million for Q3 2025 at Mereo BioPharma, down from $1.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $36.5 million in Q4 2021 to a low of $1.2 million in Q3 2025.
  • A 5-year average of $5.4 million and a median of $2.1 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: plummeted 93.93% in 2022, then grew 23.6% in 2023.
  • Mereo BioPharma's Non-Current Assets stood at $36.5 million in 2021, then tumbled by 93.93% to $2.2 million in 2022, then rose by 23.6% to $2.7 million in 2023, then crashed by 40.6% to $1.6 million in 2024, then decreased by 26.55% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Non-Current Assets are $1.2 million (Q3 2025), $1.2 million (Q2 2025), and $1.4 million (Q1 2025).